Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Bixia Tang, Zhihong Chi, Yingbo Chen, Xiufeng Liu, Di Wu, Jing Chen, Xin Song, Weifeng Wang, Lihou Dong, Haifeng Song, Hai Wu, Hui Feng, Sheng Yao, Shuikui Qin, Xiaoshi Zhang, Jun Guo
Abstract
In the earlier version of [this article][1] as it was published online on July 21, 2020 ([1][2]) and in the printed article, the Results section contained incorrect progression-free survival values at 3.6 months. The values in the abstract were correct (95% confidence interval, 2.7–5.3). The HTML
Topics & Concepts
Confidence intervalMedicineInternal medicineOncologyMelanomaMulticenter studySection (typography)Randomized controlled trialComputer scienceCancer researchOperating systemCAR-T cell therapy researchMelanoma and MAPK PathwaysCutaneous Melanoma Detection and Management